Genomics of lithium action and response
Pickard, Benjamin S. (2017) Genomics of lithium action and response. Neurotherapeutics, 14 (3). pp. 582-587. ISSN 1878-7479 (https://doi.org/10.1007/s13311-017-0554-7)
Preview |
Text.
Filename: Pickard_Neurotherapeutics_2017_Genomics_of_lithium_action_and_response.pdf
Final Published Version License: Download (380kB)| Preview |
Abstract
Lithium is the most successful mood stabiliser treatment for bipolar disorder. However, unlike conventional drugs that are designed to interact with a specific molecular target, the actions of lithium are distributed across many biological processes and pathways. Treatment response is subject to genetic variation between individuals and similar genetic variation may dictate susceptibility to side-effects. Transcriptomic, genomic and cell model research strategies have all been deployed in the search for the genetic factors and biological systems that mediate the interaction between genetics and the therapeutic actions of lithium. In this review, recent findings from genome-wide studies and patient cell lines will be summarised and discussed from a standpoint that genuine progress is being made to define clinically useful mechanisms of this treatment, to place it in the context of bipolar disorder pathology, and to move towards a time when the prescription of lithium is targeted to those individuals who will derive the greatest benefit.
ORCID iDs
Pickard, Benjamin S. ORCID: https://orcid.org/0000-0002-2374-6329;-
-
Item type: Article ID code: 60868 Dates: DateEvent31 July 2017Published21 June 2017Published Online7 June 2017AcceptedSubjects: Medicine > Pharmacy and materia medica Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 08 Jun 2017 09:46 Last modified: 02 Oct 2024 00:28 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/60868